Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPKAPK5 | Q8IW41 | 14/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617149 | 1.00 | POLB (0.38) | POLBMAPKAPK5MAPK14MAPKAPK2CYP3A4 | |
| SCHEMBL30496819 | 0.92 | POLB (0.35) | POLBMAPKAPK5MAPK14 | |
| SCHEMBL30496841 | 0.88 | POLB (0.38) | POLBKCNJ5KCNJ3 | |
| SCHEMBL25309483 | 0.86 | POLB (0.36) | POLBMAPKAPK5MAPK14MAPKAPK2KCNJ5 | |
| SCHEMBL25604948 | 0.85 | NPSR1 (0.33) | POLBMAPKAPK5MAPK14MAPKAPK2CYP3A4 | |
| SCHEMBL18799989 | 0.85 | POLB (0.40) | POLBMAPKAPK5MAPK14MAPKAPK2MAPK1 | |
| SCHEMBL24759318 | 0.85 | POLB (0.42) | POLBLMNAKCNJ5KCNJ3 | |
| SCHEMBL30270582 | 0.85 | POLB (0.42) | POLBLMNAKCNJ5KCNJ3 | |
| SCHEMBL24759465 | 0.83 | SCN9A (0.40) | POLBMAPK1LMNA | |
| SCHEMBL29963176 | 0.83 | SCN9A (0.40) | POLBMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| WO-2024046327-A1 | P38α-MK2 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4247380-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | TNF, MAPKAPK2, MAPK1 | POLB 3739/4885MAPKAPK5 5/4885MAPK14 11/4885 |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAP3K1, MAPK1, PDXK | POLB 2073/4885MAPKAPK5 44/4885MAPK14 46/4885 |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | POLB 1068/4885MAPKAPK5 848/4885MAPK14 2275/4885 |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | POLB 1068/4885MAPKAPK5 848/4885MAPK14 2275/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | POLB 2730/4885MAPKAPK5 103/4885MAPK14 339/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | POLB 3382/4885MAPKAPK5 45/4885MAPK14 152/4885 |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | POLB 1944/4885MAPKAPK5 35/4885MAPK14 47/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | POLB 1619/4885MAPKAPK5 3641/4885MAPK14 3707/4885 |
| US-20140171449-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | POLB 1944/4885MAPKAPK5 35/4885MAPK14 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.